304 related articles for article (PubMed ID: 34676266)
1. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
Godman B; Wladysiuk M; McTaggart S; Kurdi A; Allocati E; Jakovljevic M; Kalemeera F; Hoxha I; Nachtnebel A; Sauermann R; Hinteregger M; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Slabý J; Nejezchlebova R; Krulichová IS; Laius O; Selke G; Langner I; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuolienė K; Gulbinovič J; Bonanno PV; Rutkowski J; Ingeberg S; Melien Ø; Mardare I; Fürst J; MacBride-Stewart S; Holmes C; Pontes C; Zara C; Pedrola MT; Hoffmann M; Kourafalos V; Pisana A; Banzi R; Campbell S; Wettermark B
Biomed Res Int; 2021; 2021():9996193. PubMed ID: 34676266
[TBL] [Abstract][Full Text] [Related]
2. The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.
Godman B; Haque M; Leong T; Allocati E; Kumar S; Islam S; Charan J; Akter F; Kurdi A; Vassalo C; Bakar MA; Rahim SA; Sultana N; Deeba F; Khan MAH; Alam ABMM; Jahan I; Kamal ZM; Hasin H; Munzur-E-Murshid ; Nahar S; Haque M; Dutta S; Abhayanand JP; Kaur RJ; Rwegerera GM; do Nascimento RCRM; Dias Godói IP; Irfan M; Amu AA; Matowa P; Acolatse J; Incoom R; Sefah IA; Acharya J; Opanga S; Njeri LW; Kimonge D; Kwon HY; Bae S; Khuan KKP; Abubakar AR; Sani IH; Khan TA; Hussain S; Saleem Z; Malande OO; Piloya-Were T; Gambogi R; Hernandez Ortiz C; Alutuli L; Kalungia AC; Hoxha I; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Laius O; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuoliene K; Gulbinovič J; Wladysiuk M; Rutkowski J; Mardare I; Fürst J; McTaggart S; MacBride-Stewart S; Pontes C; Zara C; Tagoe ET; Banzi R; Wale J; Jakovljevic M
Front Public Health; 2021; 9():671961. PubMed ID: 34249838
[No Abstract] [Full Text] [Related]
3. Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future.
Godman B; Haque M; Kumar S; Islam S; Charan J; Akter F; Kurdi A; Allocati E; Bakar MA; Rahim SA; Sultana N; Deeba F; Halim Khan MA; Alam ABMM; Jahan I; Kamal ZM; Hasin H; Munzur-E-Murshid ; Nahar S; Haque M; Dutta S; Abhayanand JP; Kaur RJ; Acharya J; Sugahara T; Kwon HY; Bae S; Khuan KKP; Khan TA; Hussain S; Saleem Z; Pisana A; Wale J; Jakovljevic M
Curr Med Res Opin; 2021 Sep; 37(9):1529-1545. PubMed ID: 34166174
[TBL] [Abstract][Full Text] [Related]
4. Ongoing efforts to improve the management of patients with diabetes in Bangladesh and the implications.
Haque M; Islam S; Kamal ZM; Akter F; Jahan I; Rahim MSA; Sultana N; Alam AM; Munzur-E-Murshid ; Halim-Khan MA; Deeba F; Bakar MA; Nahar S; Mozaffor M; Urmi UL; Saikat TR; Islam MZ; Haque M; Iqbal S; Hossain MM; Naher N; Allocati E; Godman B
Hosp Pract (1995); 2021 Oct; 49(4):266-272. PubMed ID: 33734004
[TBL] [Abstract][Full Text] [Related]
5. Real-World Budget Impact of the Adoption of Insulin Glargine Biosimilars in Primary Care in England (2015-2018).
Agirrezabal I; Sánchez-Iriso E; Mandar K; Cabasés JM
Diabetes Care; 2020 Aug; 43(8):1767-1773. PubMed ID: 32527798
[TBL] [Abstract][Full Text] [Related]
6. The economic value of insulin glargine 300 U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspective.
Ponomareva E; Schmerold L; Sss S; Preblick R; Park S; Wilson L; Revel A
J Med Econ; 2023; 26(1):1469-1478. PubMed ID: 37916295
[TBL] [Abstract][Full Text] [Related]
7. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar vs originator insulins: Systematic review and meta-analysis.
Yamada T; Kamata R; Ishinohachi K; Shojima N; Ananiadou S; Nom H; Yamauchi T; Kadowaki T
Diabetes Obes Metab; 2018 Jul; 20(7):1787-1792. PubMed ID: 29536603
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
Russel-Szymczyk M; Valov V; Savova A; Manova M
BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
[TBL] [Abstract][Full Text] [Related]
10. Biosimilar Insulin and Costs: What Can We Expect?
Heinemann L
J Diabetes Sci Technol; 2015 Sep; 10(2):457-62. PubMed ID: 26350722
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars and Novel Insulins.
Ampudia-Blasco FJ
Am J Ther; 2020; 27(1):e52-e61. PubMed ID: 31764128
[TBL] [Abstract][Full Text] [Related]
12. Changes Associated With the Entry of a Biosimilar in the Insulin Glargine Market.
Levy J; Chowdhury ZM; Socal MP; Trujillo AJ
JAMA Intern Med; 2021 Oct; 181(10):1405-1407. PubMed ID: 34180955
[TBL] [Abstract][Full Text] [Related]
13. Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018.
Hernandez I; Good CB; Shrank WH; Gellad WF
JAMA; 2019 Apr; 321(16):1627-1629. PubMed ID: 30907933
[TBL] [Abstract][Full Text] [Related]
14. New Insulins, Biosimilars, and Insulin Therapy.
Danne T; Heinemann L; Bolinder J
Diabetes Technol Ther; 2016 Feb; 18 Suppl 1():S43-55. PubMed ID: 26836429
[No Abstract] [Full Text] [Related]
15. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
16. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
17. Introduction of biosimilar insulins in Europe.
Davies M; Dahl D; Heise T; Kiljanski J; Mathieu C
Diabet Med; 2017 Oct; 34(10):1340-1353. PubMed ID: 28608570
[TBL] [Abstract][Full Text] [Related]
18. Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey.
Chapman SR; Fitzpatrick RW; Aladul MI
BMJ Open; 2017 Jun; 7(6):e016730. PubMed ID: 28637743
[TBL] [Abstract][Full Text] [Related]
19. Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study.
Taki K; Koyanagi M; Nagaoka S; Shingaki T
Curr Med Res Opin; 2020 Dec; 36(12):1975-1983. PubMed ID: 33030354
[TBL] [Abstract][Full Text] [Related]
20. New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?
Standl E; Owen DR
Diabetes Care; 2016 Aug; 39 Suppl 2():S172-9. PubMed ID: 27440830
[No Abstract] [Full Text] [Related]
[Next] [New Search]
